| Dr Joseph G Surber, DO | |
|
2122 Manchester Expy, Columbus, GA 31904-6878 | |
| (334) 320-3077 | |
| Not Available |
| Full Name | Dr Joseph G Surber |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 28 Years |
| Location | 2122 Manchester Expy, Columbus, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598814246 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 52232 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medical Center Barbour | Eufaula, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Southland 806 Hospitalist Pllc | 3779932611 | 6 |
News Archive
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
Tel Aviv University researchers have discovered that breast cancer tumors boost their growth by recruiting stromal cells that originate in bone marrow.
Women who suffer from the frustrating and painful chronic symptoms of uterine fibroids have a safe and effective alternative to surgery according to new five-year studies presented at an annual meeting of the Society of Interventional Radiology held in April. Studies found that uterine fibroid embolization has a 73 percent success rate at five years.
Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England's (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.
› Verified 4 days ago
| Entity Name | Southland Hospitalist Services At Eufaula, Pl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235381468 PECOS PAC ID: 0446311484 Enrollment ID: O20081209000248 |
News Archive
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
Tel Aviv University researchers have discovered that breast cancer tumors boost their growth by recruiting stromal cells that originate in bone marrow.
Women who suffer from the frustrating and painful chronic symptoms of uterine fibroids have a safe and effective alternative to surgery according to new five-year studies presented at an annual meeting of the Society of Interventional Radiology held in April. Studies found that uterine fibroid embolization has a 73 percent success rate at five years.
Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England's (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.
› Verified 4 days ago
| Entity Name | Southland Medical Solutions Of Ozark, Pl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144545500 PECOS PAC ID: 6608907415 Enrollment ID: O20100623000165 |
News Archive
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
Tel Aviv University researchers have discovered that breast cancer tumors boost their growth by recruiting stromal cells that originate in bone marrow.
Women who suffer from the frustrating and painful chronic symptoms of uterine fibroids have a safe and effective alternative to surgery according to new five-year studies presented at an annual meeting of the Society of Interventional Radiology held in April. Studies found that uterine fibroid embolization has a 73 percent success rate at five years.
Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England's (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.
› Verified 4 days ago
| Entity Name | Southland Hospitalist At Ozark, Pl |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750608949 PECOS PAC ID: 2769513167 Enrollment ID: O20100629000518 |
News Archive
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
Tel Aviv University researchers have discovered that breast cancer tumors boost their growth by recruiting stromal cells that originate in bone marrow.
Women who suffer from the frustrating and painful chronic symptoms of uterine fibroids have a safe and effective alternative to surgery according to new five-year studies presented at an annual meeting of the Society of Interventional Radiology held in April. Studies found that uterine fibroid embolization has a 73 percent success rate at five years.
Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England's (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.
› Verified 4 days ago
| Entity Name | The Health Care Authority Of The City Of Eufaula |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730692641 PECOS PAC ID: 9335407659 Enrollment ID: O20180619000582 |
News Archive
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
Tel Aviv University researchers have discovered that breast cancer tumors boost their growth by recruiting stromal cells that originate in bone marrow.
Women who suffer from the frustrating and painful chronic symptoms of uterine fibroids have a safe and effective alternative to surgery according to new five-year studies presented at an annual meeting of the Society of Interventional Radiology held in April. Studies found that uterine fibroid embolization has a 73 percent success rate at five years.
Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England's (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.
› Verified 4 days ago
| Entity Name | Southland 806 Hospitalist Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033803424 PECOS PAC ID: 3779932611 Enrollment ID: O20231218001564 |
News Archive
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
Tel Aviv University researchers have discovered that breast cancer tumors boost their growth by recruiting stromal cells that originate in bone marrow.
Women who suffer from the frustrating and painful chronic symptoms of uterine fibroids have a safe and effective alternative to surgery according to new five-year studies presented at an annual meeting of the Society of Interventional Radiology held in April. Studies found that uterine fibroid embolization has a 73 percent success rate at five years.
Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England's (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph G Surber, DO 2257 Taylor Rd, Suite 200, Montgomery, AL 36117-7790 Ph: (334) 270-9914 | Dr Joseph G Surber, DO 2122 Manchester Expy, Columbus, GA 31904-6878 Ph: (334) 320-3077 |
News Archive
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
Tel Aviv University researchers have discovered that breast cancer tumors boost their growth by recruiting stromal cells that originate in bone marrow.
Women who suffer from the frustrating and painful chronic symptoms of uterine fibroids have a safe and effective alternative to surgery according to new five-year studies presented at an annual meeting of the Society of Interventional Radiology held in April. Studies found that uterine fibroid embolization has a 73 percent success rate at five years.
Acura Pharmaceuticals, Inc. and King Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration ("FDA") has publically announced the scheduling of an April 22, 2010 Advisory Committee meeting to discuss the New Drug Application ("NDA") for Acurox® (oxycodone HCl and niacin) Tablets and the results of studies evaluating the addition of niacin for the purpose of reducing the misuse of oxycodone.
The novel product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments have shown that it reduced viral replication by as much as 96 percent in the animal study. Spearheaded by Public Health England's (PHE) Deputy Director, Professor Miles Carroll, the new study described the potential treatment and has been published in the open-source preprint server bioRxiv*.
› Verified 4 days ago
Clayton Paul Michael Bellam, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 8400 Veterans Pkwy Apt 802, Columbus, GA 31909 Phone: 770-906-0084 | |
Dr. Jeffrey S Jenkins, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 10th Ave, Suite 200, Columbus, GA 31901 Phone: 706-321-3745 Fax: 706-321-3749 | |
Dr. Jefferson C Jones, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2000 10th Ave, Suite 200, Columbus, GA 31901 Phone: 706-321-3745 Fax: 706-321-3749 | |
Dr. Robert O'neil Snoddy, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 610 19th St, Columbus, GA 31901 Phone: 706-322-7884 Fax: 706-660-2167 | |
Dr. Lisa W. Gantner, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 7901 Veterans Pkwy, Columbus, GA 31909 Phone: 706-321-1223 Fax: 706-321-0819 | |
Shikha Shah, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6200 Bradley Park Dr, Columbus, GA 31904 Phone: 706-591-8080 Fax: 888-905-2571 | |
Anthony Iwelunmor, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 710 Center St, Columbus, GA 31901 Phone: 706-571-1000 |